Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Gains from Investment Securities: 2024-2025

  • Abivax's Gains from Investment Securities rose 11.83% to -$606,730 in Q2 2025 from the same period last year, while for Jun 2025 it was -$574,937, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is 221.45% up from last year.
  • Per Abivax's latest filing, its Gains from Investment Securities stood at -$606,730 for Q2 2025, which was down 153.36% from $1.1 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Gains from Investment Securities ranged from a high of $1.1 million in Q1 2025 and a low of -$688,131 during Q2 2024.
  • Moreover, its 2-year median value for Gains from Investment Securities was -$511,947 (2024), whereas its average is -$143,734.
  • Data for Abivax's Gains from Investment Securities shows a peak YoY soared of 372.58% (in 2025) over the last 5 years.
  • Over the past 2 years, Abivax's Gains from Investment Securities (Quarterly) stood at -$688,131 in 2024, then grew by 11.83% to -$606,730 in 2025.
  • Its Gains from Investment Securities stands at -$606,730 for Q2 2025, versus $1.1 million for Q1 2025 and -$688,131 for Q2 2024.